Gland Pharma Achieves 23% Revenue Growth in Q2 FY2027 Driven by Expanding CDMO Segment and US Market
Strong US sales and new product launches support a 58% rise in profit after tax to INR 2,908 million in the quarter ending September 2026
Gland Pharma Limited posted Q2 FY2027 revenue of INR 18,336 million, a 23% increase year-on-year, driven by a 31% rise in CDMO revenues contributing 45% of total revenue. EBITDA grew 53% to INR 4,804 million, with adjusted EBITDA margins at 27%. The US market led growth with 42% revenue increase, supported by new product launches and expanding injectable and CDMO segments.
Gland Pharma Limited
Earnings Call Transcript
Gland Pharma Limited reported robust financial results for the second quarter of fiscal year 2027, with revenues increasing 23% year-on-year to INR 18,336 million and a 58% rise in profit after tax to INR 2,908 million. A significant contribution came from the Contract Development and Manufacturing Organization (CDMO) business, which grew by 31% and now represents nearly half of total revenues.
The company's EBITDA rose by 53% year-on-year to INR 4,804 million in Q2 FY2027, with adjusted EBITDA at INR 5,030 million and margins standing at 27%. Revenue growth was fueled by ongoing product launches, enhanced operating leverage, and expanding customer partnerships, especially in the CDMO segment.
Gland Pharma's CDMO revenues reached INR 8,227 million in the quarter, contributing approximately 45% of total revenue, driven by production under existing contracts and new manufacturing collaborations. The business pipeline remains strong, with recent additions in respiratory microspheres and specialty formulations.
The critical injectable business also delivered solid results with revenues of INR 10,109 million, growing 18% year-on-year, supported by strong demand and wider market penetration.
Geographically, the United States continues to be the largest market, with revenues increasing 42% year-on-year to INR 11,795 million, boosted by new product launches and increased volumes. Revenues from Europe and other regulated markets grew 23% to INR 4,110 million, while revenues from other global markets reached INR 2,044 million.
The company's French CDMO platform, Cenexi, recorded revenues of EUR 41 million but reported an EBITDA loss of EUR 6 million due to planned facility shutdowns, with expectations to return to profitability from the next quarter onwards.
Highlights
- Q2 FY2027 revenue at INR 18,336 million, 23% YoY growth
- EBITDA increased 53% YoY to INR 4,804 million with 27% adjusted margins
- Profit after tax at INR 2,908 million, up 58% YoY
- CDMO business revenue up 31% YoY to INR 8,227 million, 45% of total revenue
- US market revenue grew 42% YoY to INR 11,795 million
- Four new products launched in US during Q2 FY2027, expanding portfolio and market share
Key Data Snapshot
What happened
- Gland Pharma reported Q2 FY2027 revenue of INR 18,336 million, up 23% year-on-year.
- EBITDA increased 53% year-on-year to INR 4,804 million with adjusted EBITDA margins at 27%.
- Profit after tax rose 58% year-on-year to INR 2,908 million.
- Contract Development and Manufacturing Organization (CDMO) business revenue grew 31% to INR 8,227 million, contributing 45% of total revenue.
- US market revenues increased 42% to INR 11,795 million, driven by new product launches and volume growth.
Key details
- CDMO revenues for first half FY2027 reached INR 17,142 million, representing 47% of consolidated revenues and 25% growth year-on-year.
- Cenexi's quarterly revenues stood at EUR 41 million with an EBITDA loss of EUR 6 million due to planned annual shutdowns.
- Critical injectable business revenue for Q2 FY2027 was INR 10,109 million, growing 18% year-on-year.
- Company launched four new products in the US market during the quarter.
- Growth also supported by commercial supply from signed CDMO contracts and expanded manufacturing partnerships.
Strategic context
- The company is focusing on building its sterile injectables and CDMO platform as key long-term growth drivers.
- Technology transfer activities and discussions with global clients continue to develop the CDMO pipeline.
- Expanding capabilities in respiratory products and specialty formulations.
- Plans to restore Cenexi profitability from Q3 onwards through optimizing capacity utilisation and cost control.
Highlights
- Q2 FY2027 revenue at INR 18,336 million, 23% YoY growth
- EBITDA increased 53% YoY to INR 4,804 million with 27% adjusted margins
- Profit after tax at INR 2,908 million, up 58% YoY
- CDMO business revenue up 31% YoY to INR 8,227 million, 45% of total revenue
- US market revenue grew 42% YoY to INR 11,795 million
- Four new products launched in US during Q2 FY2027, expanding portfolio and market share
Source Information
More News on Earnings Call Transcript
View allLatest corporate announcements and market updates in Earnings Call Transcript.
Sunrakshakk Industries India Limited Posts INR 265.17 Crores Revenue with 130% PAT Increase in Q2 FY27
Sunrakshakk Industries India Limited reported its Q2 FY27 financial results with revenue of INR 265.17 crores and a profit after tax of INR 16 crores, reflecting year-on-year growth of 119.20% in revenue and 130.10% in PAT, supported by expansion in its FMCG, FMCG intermediates, and edible segments.
Read Full StoryReligare Enterprises Posts INR 4,717 Crores Income and INR 145 Crores Loss After Tax in H1 FY27, Resumes Lending and Strengthens Board
Religare Enterprises Limited has reported consolidated total income of INR 4,717 crores and a loss after tax of INR 145 crores for the half-year ending September 30, 2026, marking a 19% increase in income year-on-year. The company is transitioning from preparation to execution phase by strengthening its board with RBI-approved promoter and shareholder directors, resuming lending through Religare Finvest, and advancing growth in its core financial services and insurance businesses.
Read Full StoryBlack Box Limited Posts Record Q2 FY27 Revenue of INR 1,936 Crores and Expands Order Backlog to $1.04 Billion
Black Box Limited reported its highest-ever quarterly revenue of INR 1,936 crores for Q2 FY27, marking a 22% year-on-year increase, alongside an 88% year-on-year growth in its order backlog, which reached $1.04 billion as of September 2026. Data center order bookings crossed $250 million during H1 FY27, signaling strong momentum in hyperscale digital infrastructure projects.
Read Full Story